Novel strategies for improved cancer vaccines

Expert Review of Vaccines

Volumn 8, Issue 5, 2009, Pages 567-576

  Chen, Xiaochuan ^a   Chang, Chien Hsing ^a,b   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b IMMUNOMEDICS INC   (United States)

Author keywords

Cancer stem cells; Cancer vaccine; Dendritic cells; In vivo targeted vaccination; Tolerance; Xenoantigen

Indexed keywords

CANCER VACCINE; CD20 ANTIGEN; CELECOXIB; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GEMCITABINE; GLYCOPROTEIN GP75; HETEROANTIGEN; KEYHOLE LIMPET HEMOCYANIN; MILATUZUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; NY ESO 1 ANTIGEN; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TYROSINE RELATED PROTEIN 1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER STEM CELL; CELL MATURATION; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DENDRITIC CELL; DNA IMMUNIZATION; DRUG EFFICACY; EX VIVO STUDY; EXOSOME; HELPER CELL; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LYMPHOCYTE TRANSFER; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR IMMUNITY; WART VIRUS; IMMUNOLOGY; MEDICAL RESEARCH; NEOPLASM;

BIOMEDICAL RESEARCH; CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 65649148591     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.11     Document Type: Review

References (114)

1. Srivastava PK, Old LJ. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol. Today 9(3), 78-83 (1988). (Pubitemid 18053715)
2. Melief CJ, Vasmel WL, Offringa R et al. Immunosurveillance of virus-induced tumors. Cold Spring Harb. Symp. Quant. Biol. 54, 597-603 (1989). (Pubitemid 20177632)
3. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in human: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587-617 (2007). (Pubitemid 46697918)
4. Dalgleish A, Pandha H. Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv. Cancer Res. 96, 175-190 (2007).
5. Finn OJ. Cancer immunology. N. Engl. J Med. 358(25), 2704-2715 (2008).
6. Takahashi Y, Harashima N, Kajigaya S et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J. Clin. Invest. 118(3), 1099-1109 (2008).
7. Chen J, Pang XW, Liu FF et al. PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients. Beijing Da Xue Xue Bao 38(2), 124-127 (2006).
8. Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C, Tureci O. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res. 67(19), 9528-9534 (2007). (Pubitemid 47535943)
9. Old LJ. Cancer is a somatic cell pregnancy. Cancer Immun. 7, 19 (2007). (Pubitemid 350074539)
10. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 58(3), 317-324 (2009).
11. Kruisbeek AM, Amsen D. Mechanisms underlying T-cell tolerance. Curr. Opin. Immunol. 8(2), 233-244 (1996). (Pubitemid 26166989)
12. Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol. 71, 229-265 (1999). (Pubitemid 30227736)
13. Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 184(4), 1259-1268 (1996). (Pubitemid 26354681)
14. Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 380(6574), 495-498 (1996). (Pubitemid 26110635)
15. Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167(12), 7150-7156 (2001). * First and only clinical study on xenoantigen vaccination against cancer. (Pubitemid 33144213)
16. Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 99(10), 3748-3755 (2002). (Pubitemid 34534547)
17. + T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin. Cancer Res. 11(1), 370-379 (2005). (Pubitemid 40075817)
18. Weber LW, Bowne WB, Wolchok JD et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102(6), 1258-1264 (1998). (Pubitemid 28436286)
19. Hawkins WG, Gold JS, Blachere NE et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J. Surg. Res. 102(2), 137-143 (2002). (Pubitemid 34969459)
20. Lu Y, Wei YQ, Tian L et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J. Immunol. 170(6), 3162-3170 (2003). (Pubitemid 36302193)
21. Pupa SM, Iezzi M, Di Carlo E et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65(3), 1071-1078 (2005). (Pubitemid 40216470)
22. Gallo P, Dharmapuri S, Nuzzo M et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113(1), 67-77 (2005). (Pubitemid 39507312)
23. Ko HJ, Kim YJ, Kim YS et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67(15), 7477-7486 (2007).
24. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res. 66(10), 5452-5460 (2006). (Pubitemid 43844973)
25. + T-cell immunity and break immune tolerance, whereas self-antigens cannot. (Pubitemid 47037531)
26. Weigle WO. The induction of autoimmunity in rabbits following injection of heterologous or altered homologous thyroglobulin J. Exp. Med. 121, 289-308 (1965).
27. Grünewald J, Tsao ML, Perera R et al. Immunochemical termination of self-tolerance. Proc. Natl Acad. Sci. USA 105(32), 11276-11280 (2008).
28. Lazoura E, Lodding J, Farrugia W et al. Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology 119(3), 306-316 (2006). (Pubitemid 44571048)
29. + T cells in anti-tumor immune responses. Immunol. Rev. 222, 129-144 (2008).
30. + T-cell epitopes. (Pubitemid 44277801)
31. + T lymphocytes. Nature 421(6925), 852-856 (2003). (Pubitemid 36254145)
32. Shedlock DJ, Shen H. Requirement for CD4 T-cell help in generating functional CD8 T-cell memory. Science 300(5617), 337-339 (2003). (Pubitemid 36433726)
33. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300(5617), 339-342 (2003). (Pubitemid 36433727)
34. + helper T cells induces potent primary and secondary tumor rejection. Blood 106(9), 2995-3003 (2005). (Pubitemid 41565891)
35. + T cells. J. Exp. Med. 200(6), 701-712 (2004). (Pubitemid 39299457)
36. + T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood 107(5), 1963-1969 (2006). (Pubitemid 43289378)
37. + CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169(11), 6376-6385 (2002). (Pubitemid 36903486)
38. Stein R, Mattes MJ, Cardillo TM et al. CD74, a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res. 13(18 Pt 2), 5556s-5563s (2007). (Pubitemid 47510387)
39. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends Immunol. 24(5), 264-268 (2003). (Pubitemid 36555966)
40. Diebold SS, Cotten M, Koch N, Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8(6), 487-493 (2001). (Pubitemid 32266404)
41. Rowe HM, Lopes L, Ikeda Y et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther. 13(2), 310-319 (2006). (Pubitemid 43056896)
42. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J. Immunol. 180(5), 3339-3346 (2008).
43. Grujic M, Holst PJ, Christensen JP, Thomsen AR. Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. J. Gen. Virol. 90(Pt 2), 414-422 (2009).
44. Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 65(21), 10059-10067 (2005). (Pubitemid 41541488)
45. + T cell responses in vitro. J. Immunother. 30(1), 75-82 (2007). (Pubitemid 46052205)
46. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. α-type-1 polarized dendritic cells, a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64(17), 5934-5937 (2004). •• Describes fully matured, type-1 polarized dendritic cells (DCs; αDC1s) with a high level of IL-12 production, chemokine receptor type 7 expression, Th1 polarization and potent induction of tumor-specific CTLs. (Pubitemid 39129387)
47. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J. Leukoc. Biol. 84(1), 319-325 (2008).
48. Gustafsson K, Ingelsten M, Bergqvist L, Nystrom J, Andersson B, Karlsson-Parra A. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res. 68(14), 5965-5971 (2008).
49. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68(14), 5972-5978 (2008). • Demonstrates that the maturation cocktails determine the ability of mature DCs to interact with Tregs, and the αDC1, unlike standard DCs, has the least ability to attract and expand Tregs.
50. Parlato S, Santini SM, Lapenta C et al. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98(10), 3022-3029 (2001).
51. Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-α skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171(7), 3385-3393 (2003). (Pubitemid 37254538)
52. +-expressing dendritic cells with potent functional activities in vitro and in vivo. J. Immunol. 180(3), 1462-1470 (2008).
53. Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of α-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine 26(23), 2824-2832 (2008).
54. Kang SJ, Cresswell P. Calnexin, calreticulin and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain. J. Biol. Chem. 277(47), 44838-44844 (2002).
55. Han S, Wang B, Cotter MJ et al. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol. Ther. 16(2), 269-279 (2008).
56. Chaput N, Schartz NE, Andre F et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive TcI lymphocytes leading to tumor rejection. J. Immunol. 172(4), 2137-2146 (2004). (Pubitemid 38182359)
57. Cho JA, Yeo, DJ, Son HY et al. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int. J. Cancer 114(4), 613-622 (2005).
58. Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120(1), 90-102 (2007).
59. + T-cell-based vaccine that accretes DC-derived exosomes that can counteract Treg-mediated immune suppression and stimulate efficient central memory CTL responses.
60. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007). (Pubitemid 47480309)
61. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199(6), 815-824 (2004). (Pubitemid 38375201)
62. Kretz-Rommel A, Qin F, Dakappagari N et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J. Immunother. 30(7), 715-726 (2007). (Pubitemid 47480755)
63. Yang L, Yang H, Rideout K et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26(3), 326-334 (2008).
64. + T-cell responses. J. Virol. 82(1), 86-95 (2008). (Pubitemid 350309126)
65. He LZ, Crocker A, Lee J et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol. 178(10), 6259-6267 (2007). (Pubitemid 46717409)
66. Ramakrishna V, Treml JF, Vitale L et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 172(5), 2845-2852 (2004). (Pubitemid 38263669)
67. + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203(3), 607-617 (2006).
68. Gurer C, Strowig T, Brilot F et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112(4), 1231-1239 (2008).
69. Tacken PJ, de Vries IJ, Gijzen K et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106(4), 1278-1285 (2005). (Pubitemid 41129591)
70. Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17(3), 353-362 (2002). (Pubitemid 35279555)
71. Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl Acad. Sci. USA 87(19), 7698-7702 (1990). (Pubitemid 20341784)
72. Chen X, Chang CH, Goldenberg DM. Efficient binding, but moderate modulation, of human dendritic cell functions by milatuzumab, a humanized anti-CD74 monoclonal antibody. Presented at: The 50th American Society of Hematology Annual Meeting. San Francisco, CA, USA, 6-9 December 2008. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 2649).
73. Clark EA, Grabstein KH, Shu GL. Cultured human follicular dendritic cells. Growth characteristics and interactions with B lymphocytes. J. Immunol. 148(11), 3327-3335 (1992).
74. Ding C, Wang L, Marroquin J, Yan J. Targeting of antigens to B cells augments antigen-specific T cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood 112(7), 2817-2825 (2008). • Demonstrates that targeting antigens to B cells breaks immune tolerance to Mucin 1, suggesting that wider targeting of antigens to APCs may be superior only to targeting to DCs.
75. Mouries J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112(9), 3713-3722 (2008).
76. Leung SO, Goldenberg DM, Dion AS et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol. Immunol. 32(17-18), 1416-1427 (1995). (Pubitemid 26064907)
77. Losman MJ, Hansen HJ, Dworak H et al. Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer 80(12 Suppl.), 2660-2666 (1997). (Pubitemid 28009524)
78. Stein R, Qu Z, Cardillo TM et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104(12), 3705-3711 (2004). (Pubitemid 39564448)
79. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl Acad. Sci. USA 96(15), 8639-8644 (1999). (Pubitemid 29354844)
80. Rosinski KV, Fujii N, Mito JK et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood 111(9), 4817-4826 (2008).
81. KawaseT, Akatsuka Y, Torikai H et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 110(3), 1055-1063 (2007). (Pubitemid 47267448)
82. Moreaux J, Hose D, Reme T etal. CD200 is a new prognostic factor in multiple myeloma. Blood 108(13), 4194-4197 (2006). (Pubitemid 44913292)
83. Tonks A, Hills R, White P et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3), 566-568 (2007). (Pubitemid 46306574)
84. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 364(4), 778-782 (2007). • Demonstrates that CD200, an immunosuppressive glycoprotein, is expressed in multiple types of cancer stem cells, which raises the possibility that cancer stem cells may have the potential of immune evasion facilitated by CD200 expression. (Pubitemid 350103695)
85. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 29(10), 464-468 (2008).
86. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther. 16(7), 799-810 (2005). (Pubitemid 40982329)
87. de Witte MA, Bendle GM, van den Boom MD et al. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol. 181(4), 2563-2571 (2008).
88. de Witte MA, Jorritsma A, Kaiser A et al. Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 181(7), 5128-5136 (2008).
89. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006). (Pubitemid 44547756)
90. Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp. Biol. Med. (Maywood) 232(9), 1130-1141 (2007). (Pubitemid 47503054)
91. North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J. Exp. Med. 164(5), 1652-1666 (1986).
92. + suppressor T-cells. Cancer Res. 49(7), 1649-1654 (1989). (Pubitemid 19108381)
93. + T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591-1602 (2005). (Pubitemid 40723662)
94. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316-5326 (2004). (Pubitemid 39100466)
95. Antonia SJ, MirzaN, Frickel et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12(3 Pt 1), 878-887 (2006). (Pubitemid 43259871)
96. Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J. Clin. Pathol. 59(4), 382-386 (2006).
97. Sharma S, Stolina M, Yang SC et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9(3), 961-968 (2003). (Pubitemid 36323698)
98. + T regulatory cell activities in lung cancer. Cancer Res. 65(12), 5211-5220 (2005). (Pubitemid 40827331)
99. Basu GD, Tinder TL, Bradley JM et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177(4), 2391-2402 (2006). (Pubitemid 44201000)
100. Mukherjee P, Basu GD, Tinder TL et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 182(1), 216-224 (2009).
101. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA CancerJ. Clin. 56(4), 226-243 (2006). (Pubitemid 44175051)
102. Sharkey RM, Goldenberg DM. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Deliv. Rev. 60(12), 1407-1420 (2008).
103. Ofran Y, Ritz J. Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. Clin. Cancer Res. 14(16), 4997-4999 (2008).
104. + cytotoxic T cells from renal cell carcinoma patients after allogenic hematopoietic cell transplantation. Clin. Cancer Res. 14(16), 5260-5269 (2008).
105. Aqui NA, June CH. Post-transplant adoptive T-cell immunotherapy. Best Pract. Res. Clin. Haematol. 21(3), 503-519 (2008).
106. Anderson LD Jr, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus tumor activity without exacerbating graft-versus-host disease. Blood 95(7), 2426-2433 (2000). (Pubitemid 30167746)
107. Teshima T, Mach N, Hill GR et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61(1), 162-171 (2001). (Pubitemid 32095714)
108. Moyer JS, Maine G, Mule JJ. Early vaccination with tumor lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol. Blood Marrow Transplant. 12(10), 1010-1019 (2006).
109. Kitawaki T, Kadowaki N, Kondo T et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am. J. Hematol. 83(4), 315-317 (2008).
110. Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L, Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63(22), 7942-7949 (2003). (Pubitemid 37466731)
111. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev. 58(8), 931-947 (2006). (Pubitemid 44709263)
112. Goldberg SM, Bartido SM, Gardner JP et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin. CancerRes. 11(22), 8114-8121 (2005). (Pubitemid 41698756)
113. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 68(3), 861-869 (2008).
114. Barefoot B, Thornburg NJ, Barouch DH et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26(48), 6108-6118 (2008).